...
Dryness & GSM faq

What to do if I get spotting or burning after treatment?

What to do if I get spotting or burning after treatment? Mild, short-lived spotting or a warm, sunburn-like sensation can occur after gentle vaginal laser/radiofrequency or superficial injectables, and usually settles with low-friction care. Pause irritants, use a generous lubricant, and monitor for 48–72 hours. However, malodorous discharge, fever, severe pelvic pain, visible blood in urine, or new post-menopausal bleeding need medical assessment. Educational only. Results vary. Not a cure.

Clinical Context

Who is most likely to notice spotting/burning? People with very dry, fragile epithelium from GSM, entrance-focused soreness, or recent higher-friction activity. Warming/tingling products, perfumes, and high-osmolality lubricants can magnify sting. Precision at the vestibule and switching to minimal-ingredient products reduce setbacks.

Who should pause and seek review? Anyone with malodorous discharge, fever, severe pelvic pain, visible haematuria, or new post-menopausal bleeding. Procedures should be deferred if you have active BV/thrush/UTI or are recovering from pelvic/perineal surgery without clearance. Severe fish allergy generally excludes salmon-derived polynucleotides.

Next steps you can take now. Strip back to lukewarm water and a bland emollient as a soap substitute; schedule a moisturiser 2–4 nights weekly; use a generous, compatible lubricant (silicone-based often gives the longest glide for dyspareunia); and restart intimacy only when settled. Educational only. Results vary. Not a cure.

Evidence-Based Approaches

Patient-friendly basics (UK): The NHS explains symptoms, self-care and when to seek help for vaginal dryness, including irritation clues and practical soothing measures.

Guideline framing: The NICE Menopause Guideline (NG23) recommends information on vaginal moisturisers and lubricants and considering low-dose local vaginal oestrogen when GSM affects quality of life; this supports a foundations-first approach and safe escalation.

Prescribing/product detail: Dosing and cautions for local vaginal oestrogens and prasterone (DHEA) are listed in the British National Formulary (BNF), including technique tips that reduce stinging (e.g., vestibule targeting with creams).

Effectiveness benchmarks: Systematic reviews in the Cochrane Library show local vaginal oestrogens improve dryness, soreness, dyspareunia and pH versus placebo across creams, tablets/pessaries and rings—useful context when judging post-procedure improvements.

Pathophysiology detail: Peer-reviewed overviews indexed on PubMed describe GSM biology (thinner epithelium, higher pH, fewer lactobacilli) and clarify why low-friction aftercare plus local therapy often settle burning faster than changing devices alone.